Major Corporate Developments: Hengrui Pharma (01276) announced that its SHR-1819 injection and SHR-1905 injection have received drug clinical trial approval notices. Henlius (02696) disclosed that the clinical trial application for PIMURUTAMAB HLX07 combined with Hansizhuang® and chemotherapy for the treatment of advanced squamous non-small cell lung cancer has been approved by the National Medical Products Administration. Baiyunshan (00874) reported that the clinical trial application for Xuhanting Granules for children with recurrent respiratory tract infections has been approved. PegBio Co-B (02565) has entered into an exclusive commercialization partnership for Paidakang in mainland China with Tenry Pharmaceutical, targeting cumulative sales exceeding RMB 10 billion and receiving approximately HKD 140 million in rights and interests. Jinshi Pharmaceutical Group (01093) announced that the highly selective PDE4B inhibitor (SYH2059 inhalation powder) has received clinical trial approval in China. Ant Group's acquisition offer for Bright Smart (01428) has been approved, with trading set to resume on March 17.

Operational Performance: China Lilang (01234) released its annual results, reporting a profit attributable to shareholders of RMB 502 million, a 9% year-on-year increase. Q Technology (01478) announced annual results, with profit attributable to shareholders reaching RMB 1.494 billion, up 435.22% year-on-year. Kingboard Holdings (00148) reported annual results, showing a profit attributable to shareholders of HKD 4.402 billion, a 169.98% year-on-year increase. Chow Sang Sang (00116) projected a profit attributable to shareholders from continuing operations for the 2025 fiscal year of approximately HKD 1.6 to 1.7 billion. Leapmotor (09863) reported a net profit of RMB 540 million for 2025, with vehicle sales doubling for the second consecutive year. Sinopec Oilfield Service (01033) disclosed its 2025 results, showing a net profit attributable to owners of approximately RMB 659 million, a 4.3% year-on-year increase. CMS Pharma (00867) announced its 2025 results, with profit attributable to owners of approximately RMB 1.489 billion, an 8.08% year-on-year decrease.